Immix Biopharma (NASDAQ:IMMX) Announces Earnings Results, Beats Estimates By $0.09 EPS

Immix Biopharma (NASDAQ:IMMX) issued its quarterly earnings data on Monday. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09, Zacks reports.

Immix Biopharma Price Performance

NASDAQ:IMMX traded down $0.02 during mid-day trading on Wednesday, hitting $1.83. 12,323 shares of the company’s stock were exchanged, compared to its average volume of 133,311. The company has a market cap of $50.34 million, a PE ratio of -2.15 and a beta of 0.26. Immix Biopharma has a one year low of $1.26 and a one year high of $3.23. The business has a fifty day moving average price of $1.86 and a 200 day moving average price of $1.86.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Immix Biopharma in a research report on Monday, February 10th.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.